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This symposium reviews several important aspects of the
pathophysiology and treatment of the disease. The major
emphasis of the symposium is on the role of bone and
subchondral bone in the pathogenesis of osteoarthritis
(OA) and the potential role of bone-modifying agents as
disease-modifying agents in the treatment of this disease.
A number of new concepts about the pathogenesis of OA
have been described in the last few decades. This has
been made possible through a large body of research
undertaken by several investigator and research groups.
The major role, played by a number of dedicated people
who have created the proper environment to support this
research, have made it possible for the international com-
munity to understand and appreciate such efforts, and this
should be recognized. This meeting is quite unique, as it
brings together expertise from two major fields of muscu-
loskeletal research; bone and osteoarthritis. Hopefully this
is not the last time.
One may question the rationale behind such a venture.
Well, we simply believe that it represents a logical ap-
proach to understanding the pathophysiology and future
treatment of the disease. Recent advances in the field of
osteoarthritis research have clearly shown that osteoarthri-
tis is a disease with the global involvement of the three
major tissues of the joints, namely, cartilage, synovium, and
subchondral bone. The participation, and the role of syno-
vial inflammation in the progression of the structural
changes of OA is now a widely accepted concept.
The morphological changes that take place at the
subchondral bone level have been studied for many years,
and an association between these changes and the
initiation and/or progression of the disease have been
suggested. Moreover, a number of studies have now pro-
vided strong evidence that even in the early stage of OA, a
large number of factors such as cytokine and growth
factors, are present in excessive amounts in this tissue.
These are likely capable not only of locally modifying the
bone metabolism, but also of inducing cartilage remodeling
and structural changes. Experimental studies indicate that
compounds or drugs that can influence bone metabolism
may also modify the progression of OA. This has allowed
for a better understanding and appreciation of the role of a
number of risk factors in the development of OA. Similarly,
the work done on clinical trial outcomes has brought to
light the necessity of improving the precision of a number
of methods used to evaluate the effectiveness of treatment.
This symposium also aims to bring forward the necessity
of discussing and evaluating the technology used to objec-
tively evaluate and quantify the structural changes of
osteoarthritis. Additionally, we have time for discussion of
pertinent topics in OA research including how to evaluate
the disease in the clinic, and identify patients at risk of
progression.
We hope you will enjoy and appreciate the exciting
exchange about the very challenging disease that is oste-
oarthritis. We would like to thank Procter & Gamble, and in
particular, Dr Joan Meyer, for their support in organizing
this symposium. We would also like to thank all of the
executives at Procter & Gamble, as well as all of the
support staff, that have been worked very hard at putting
this symposium together. It would not have been possible
without the help of all of these people.
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